blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3805404

EP3805404 - GENE MUTATIONS AND COPY NUMBER ALTERATIONS OF EGFR, KRAS AND MET [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  09.06.2023
Database last updated on 31.08.2024
FormerRequest for examination was made
Status updated on  22.10.2021
FormerThe application has been published
Status updated on  12.03.2021
Most recent event   Tooltip28.05.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Board of Regents, The University of Texas System
210 West 7th Street
Austin, TX 78701 / US
For all designated states
Guardant Health, Inc.
3100 Hanover Street
Palo Alto, CA 94304 / US
[2024/14]
Former [2021/15]For all designated states
Board of Regents, The University of Texas System
210 West 7th Street
Austin, TX 78701 / US
For all designated states
Guardant Health, Inc.
505 Penobscot Drive
Redwood City, CA 94063 / US
Inventor(s)01 / KOPETZ, Scott
201 West 7th Street
Suite 820
Austin, TX 78701 / US
02 / TALASAZ, AmirAli
2181 Camino A
Los Cerros
Menlo Park, CA 94025 / US
 [2021/15]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2021/15]Marshall, Cameron John
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date20209515.413.05.2015
[2021/15]
Priority number, dateUS201461992877P13.05.2014         Original published format: US 201461992877 P
US201462004749P29.05.2014         Original published format: US 201462004749 P
[2021/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3805404
Date:14.04.2021
Language:EN
[2021/15]
Search report(s)(Supplementary) European search report - dispatched on:EP12.03.2021
ClassificationIPC:C12Q1/68, A61K39/395, C07K14/71
[2021/15]
CPC:
C12Q1/6886 (EP,US); C07K14/71 (EP,US); C07K14/82 (EP,US);
C07K16/2863 (EP,US); C07K16/30 (EP,US); G16B20/10 (EP,US);
G16B20/20 (EP,US); G16B99/00 (EP,US); A61K2039/505 (EP,US);
C07K2317/21 (US); C12Q2600/106 (EP,US); C12Q2600/156 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/47]
Former [2021/15]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:GENMUTATIONEN UND KOPIENZAHLÄNDERUNGEN VON EGFR, KRAS UND MET[2021/15]
English:GENE MUTATIONS AND COPY NUMBER ALTERATIONS OF EGFR, KRAS AND MET[2021/15]
French:MUTATIONS GÉNIQUES ET ALTÉRATIONS DU NOMBRE DE COPIES DE EGFR, KRAS ET MET[2021/15]
Examination procedure14.10.2021Amendment by applicant (claims and/or description)
14.10.2021Examination requested  [2021/47]
14.10.2021Date on which the examining division has become responsible
09.06.2023Despatch of a communication from the examining division (Time limit: M04)
19.10.2023Reply to a communication from the examining division
Parent application(s)   TooltipEP15792393.9  / EP3143163
Fees paidRenewal fee
24.11.2020Renewal fee patent year 03
24.11.2020Renewal fee patent year 04
24.11.2020Renewal fee patent year 05
24.11.2020Renewal fee patent year 06
27.05.2021Renewal fee patent year 07
27.05.2022Renewal fee patent year 08
30.05.2023Renewal fee patent year 09
28.05.2024Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO2008112274  (AMGEN INC [US], et al) [X] 1,3,6,9-15 * the whole document *;
 [X]WO2010145796  (MERCK PATENT GMBH [DE], et al) [X] 1,3,6,8-11,14,15 * the whole document *;
 [X]WO2011028540  (GENENTECH INC [US], et al) [X] 1,3,6,9-11,14,15 * the whole document *;
 [X]WO2012131092  (SIGNATURE DIAGNOSTICS AG [DE], et al) [X] 1,3,6,9-15 * the whole document *;
 [XP]WO2014182521  (MEDIMMUNE LLC [US], et al) [XP] 1-3,6,9-15 * the whole document *;
 [X]  - SANDRA MISALE ET AL, "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer", NATURE, London, (20120613), doi:10.1038/nature11156, ISSN 0028-0836, XP055287051 [X] 1-3,6,9-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/nature11156
 [X]  - F. MOLINARI ET AL, "Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer", CLINICAL CANCER RESEARCH, (20110715), vol. 17, no. 14, doi:10.1158/1078-0432.CCR-10-3137, ISSN 1078-0432, pages 4901 - 4914, XP055113596 [X] 1-3,6,9-15 * the whole document *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-10-3137
 [X]  - DE ROOCK W ET AL, "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 11, no. 8, doi:10.1016/S1470-2045(10)70130-3, ISSN 1470-2045, (20100801), pages 753 - 762, (20100801), XP027598757 [X] 1-3,6,9-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1470-2045(10)70130-3
 [X]  - WENDY DE ROOCK ET AL, "KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer", LANCET ONCOLOGY, (20101215), vol. 12, doi:10.1016/S1470-2045(10)70209-6, pages 594 - 603, XP055180339 [X] 1,3,6,9-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1470-2045(10)70209-6
 [I]  - FLORENT MOULIERE ET AL, "Circulating cell-free DNA from colorectal cancer patients reveal high KRAS or BRAF mutation load", vol. 6, no. 3, doi:10.1593/TLO.12445, ISSN 1944-7124, (20130601), pages 319 - 328, TRANSLATIONAL ONCOLOGY, NEOPLASIA PRESS, UNITED STATES, URL: http://www.sciencedirect.com/science/article/pii/S1936523313800836, XP002730499 [I] 7,8 * the whole document *

DOI:   http://dx.doi.org/10.1593/TLO.12445
 [I]  - Spindler ET AL, "Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan | Clinical Cancer Research", CLIN CANCER RES., doi:10.1158/1078-0432.CCR-11-0564, (20120215), page 1177, URL: http://clincancerres.aacrjournals.org/content/18/4/1177.full-text.pdf, (20160907), XP055300413 [I] 7,8 * the whole document *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-11-0564
by applicantWO2014039556
    - "NCBI", Database accession no. NP _001120972.1
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.